000 02182 am a22002773u 4500
042 _adc
100 1 0 _aBautista, Javier S.
_eauthor
_92814
700 1 0 _aFalabella, Micol
_eauthor
_92815
700 1 0 _aFlannery, Padraig J.
_eauthor
_92816
700 1 0 _aHanna, Michael G.
_eauthor
_92817
700 1 0 _aHeales, Simon J.R.
_eauthor
_92818
700 1 0 _aPope, Simon A.S.
_eauthor
_92819
700 1 0 _aPitceathly, Robert D.S.
_eauthor
_92820
245 0 0 _aAdvances in methods to analyse cardiolipin and their clinical applications
260 _c2022-12.
500 _a/pmc/articles/PMC7614147/
500 _a/pubmed/36751553
520 _aCardiolipin (CL) is a mitochondria-exclusive phospholipid, primarily localised within the inner mitochondrial membrane, that plays an essential role in mitochondrial architecture and function. Aberrant CL content, structure, and localisation have all been linked to impaired mitochondrial activity and are observed in the pathophysiology of cancer and neurological, cardiovascular, and metabolic disorders. The detection, quantification, and localisation of CL species is a valuable tool to investigate mitochondrial dysfunction and the pathophysiological mechanisms underpinning several human disorders. CL is measured using liquid chromatography, usually combined with mass spectrometry, mass spectrometry imaging, shotgun lipidomics, ion mobility spectrometry, fluorometry, and radiolabelling. This review summarises available methods to analyse CL, with a particular focus on modern mass spectrometry, and evaluates their advantages and limitations. We provide guidance aimed at selecting the most appropriate technique, or combination of techniques, when analysing CL in different model systems, and highlight the clinical contexts in which measuring CL is relevant.
540 _a
540 _ahttps://creativecommons.org/licenses/by/4.0/This work is licensed under a CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) International license.
546 _aen
690 _aArticle
655 7 _aText
_2local
786 0 _nTrends Analyt Chem
856 4 1 _uhttp://dx.doi.org/10.1016/j.trac.2022.116808
_zConnect to this object online.
999 _c963
_d963